OFIX / Orthofix Medical Inc.'s (OFIX) CEO Jon Serbousek on Q2 2022 Results - Earnings Call Transcript

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod. more_horizontal

All three fired executives came over late last year in the merger with SeaSpine. Chairman of the Board Catherine Burzik is stepping in as the interim more_horizontal

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation Sys more_horizontal

Orthofix Medical Inc.'s merger with SeaSpine has not significantly impacted investor sentiment or market expectations. Despite reasonable Q1 financial more_horizontal

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant more_horizontal

Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alexa Huerta - Senior Director, Inves more_horizontal

Orthofix (OFIX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0. more_horizontal

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter. more_horizontal